Accessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

Eli Lilly’s Stock: Time to Buy or Hold?

Timothy SykesAvatar
Written by Timothy Sykes Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs
Updated 4/17/2025, 2:32 pm ET 6 min read
Eli Lilly’s Stock: Time to Buy or Hold? Thumbnail

In this article

  • LLY-0.16%
    LLY - NYSEEli Lilly and Company
    $778.00-1.28 (-0.16%)
    Volume:  1.99M
    Float:  938.26M
    $773.00Day Low/High$783.55

Eli Lilly and Company’s stocks have been trading up by 16.48 percent due to promising FDA designations.

Recent Developments

  • Goldman Sachs has moved Eli Lilly’s rating from Neutral to Buy with a reduced target price of $888. Despite the cut from $892, this recommendation comes as a nod to the company’s robust stance in the booming anti-obesity sector.

Candlestick Chart

Live Update At 13:31:58 EST: On Thursday, April 17, 2025 Eli Lilly and Company stock [NYSE: LLY] is trending up by 16.48%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

  • Guggenheim has trimmed Eli Lilly’s price target to $928 from $973. However, it retains a Buy rating, emphasizing the promising outlook for their endeavor into the tirzepatide franchise, with strong projections for 2025.

  • Eli Lilly has published positive Phase 2 outcomes for their drug lepodisiran with a notable drop in lipoprotein(a) levels, a significant heart disease risk element.

  • With the launch of Mounjaro, targeting diabetes and weight loss, Eli Lilly is rapidly expanding its footprint in the Indian market. This signifies a rising demand for solutions in metabolic disorders across the region.

  • Morgan Stanley has also lowered the price target for Eli Lilly stocks from $1,146 to $1,124, while maintaining its Overweight rating for the pharmaceutical giant.

A Quick Tour of Eli Lilly’s Financial Landscape

In the high-stakes world of trading, success often comes down to making strategic decisions that prioritize risk management. Many traders face the temptation of riding out losing positions in the hopes of a turnaround, but this approach can lead to significant losses. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.” His advice underscores the importance of avoiding unnecessary risks and emphasizes that breaking even is preferable to accumulating losses. Successful traders understand the need to preserve capital, even if it means exiting a position without profit.

Eli Lilly, a formidable player in healthcare, witnessed a remarkable rise in stock prices touching a high of $858 on Apr 17, 2025 — it’s clear the stock is on quite the ride. Despite intermittent dips, the trend has shown resilience, closing at $855.99 on the same day. This performance reflects the company’s strategic initiatives and robust earnings.

According to the financial reports, Eli Lilly sports intriguing ratios, like a price-to-earnings ratio of 62.76, underlining its market valuation allure. The balance sheet looks hearty, with liabilities under control compared to assets and a debt to equity ratio of 2.37, indicating manageable leverage.

In terms of profitability, the company boasted an EBIT margin of 29%, supported by a commendable gross margin of 81.3%. This paints a picture of efficient operations driving profit potential. The revenue for the period climbed to about $45B, with significant growth across a five-year trajectory.

The latest press releases indicate the strategic expansion into India through Mounjaro’s launch, promising substantial market penetration. Diabetes and obesity treatment sectors are burgeoning worldwide, particularly in populous arenas like India, forecasting promising returns for Eli Lilly.

Analyzing the Strategic Impacts

Goldman Sachs’ Bold Move

The decision by Goldman Sachs to elevate Eli Lilly’s rating highlights potential undervaluation gaps exploited by the stock’s impending rise. Tipping the scales with a Buy rating signals confidence in Eli Lilly’s ability to capitalize on the anti-obesity drug wave. This bullish sentiment aligns with the stock’s slight rally, giving momentum to shareholders who weigh long-term gains.

Guggenheim’s Adjustments

Guggenheim’s lowering of the stock price target stems from cautious adjustments ahead of quarterly earnings. Yet, the persistent Buy rating signifies the belief in Eli Lilly’s growth, particularly with the tirzepatide franchise’s impact looming over 2025’s projections.

More Breaking News

Lepodisiran’s Success

The notable phase 2 trial results for lepodisiran showcase Eli Lilly’s clinical prowess in reducing cardiovascular risks. This should not only entice investors but provides confidence in the company’s ongoing R&D capabilities, crafting a narrative of consistent innovation driving market enthusiasm.

Mounjaro’s Indian Expansion

Eli Lilly’s strategic entry into India with its diabetic and weight-loss solution, Mounjaro, is pivotal. It aims to capture an underserved market plagued by rising diabetes rates. The continued expansion fortifies Eli Lilly’s global reach, potentially opening revenue streams from an expansive customer base in Asia.

Legal Action Against Drug Compounders

Eli Lilly’s assertive legal maneuvers against generic manufactures underscore its commitment to safeguarding intellectual property, reflecting a strategy to secure revenue streams amid rising imitation threats. This proactive stance sends a reassuring message about maintaining the stock’s perceived value.

Summing It Up

Eli Lilly stands at a pivotal junction where tactical innovations fortify its position amid expanding global health challenges. Thus, current bullish developments stem from insights about solid results from strategic positioning in emerging markets, robust R&D outcomes, and reaffirmations from institutional endorsements. As millionaire penny stock trader and teacher Tim Sykes says, “It’s better to go home at zero than to go home in the red.” Tying these threads together, traders might find that Eli Lilly’s stock presents itself as an enticing candidate to explore, weighing the comprehensive projections and planned initiatives on the horizon.

This content is produced using automated systems designed to deliver timely stock news. All material is reviewed by our editorial team and is provided solely for informational and entertainment purposes. It does not constitute professional investment advice. For additional details, please refer to our [Terms of Service]

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Timothy Sykes

Tim Sykes is a penny stock trader and teacher who became a self-made millionaire by the age of 22 by trading $12,415 of bar mitzvah money. After becoming disenchanted with the hedge fund world, he established the Tim Sykes Trading Challenge to teach aspiring traders how to follow his trading strategies. He’s been featured in a variety of media outlets including CNN, Larry King, Steve Harvey, Forbes, Men’s Journal, and more. He’s also an active philanthropist and environmental activist, a co-founder of Karmagawa, and has donated millions of dollars to charity.
Read More

In this article (YTD Performance)

  • LLY+0.15%
    LLY - NYSEEli Lilly and Company
    $778.00-1.28 (-0.16%)
    Volume:  1.99M
    Float:  938.26M
    $773.00Day Low/High$783.55

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM
notification icon
Subscribe to receive notifications